Pressemitteilungen zu dem Thema helius medical technologies


Unterkategorien

PresseMitteilungen zu dem Schlagwort helius medical technologies


Helius Medical Technologies Receives First of Two Human Performance Patents

NEWTOWN, PA -- (Marketwired) -- 05/23/17 -- Helius Medical Technologies, Inc. (TSX: HSM)(TSX: HSM.S)(TSX: HSM.WT.S)(OTCQB: HSDT) ("Helius" or the "Company") announced today that it has been issued its first method patent (U.S. Patent No. 9,656,069) that features claims directed to the use of the PoNS™ device for human performance improvement rather than rehabilitation therapy. The ''069 patent is the first member of the existing family of patents the company has r ...


23.05.2017

Helius Medical Technologies Receives Two Medical Method Patents

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 04/17/17 -- Helius Medical Technologies, Inc. (TSX: HSM)(TSX: HSM.S)(TSX: HSM.WT.S)(OTCQB: HSDT) ("Helius" or the "Company") announced today that it has been issued two medical method patents (U.S. Patent Nos. 5,597,501 and 5,597,504) that together further protect the intellectual property rights for its core asset, the PoNS™ device therapeutic techniques. These patents bolster the current family of PoNS patents protecting various f ...


17.04.2017

Helius Medical Technologies Signs 5-Year Lease for Corporate Headquarters in Newtown, PA

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 04/10/17 -- Helius Medical Technologies, Inc. (TSX: HSM)(TSX: HSM.S)(TSX: HSM.WT.S)(OTCQB: HSDT) ("Helius" or the "Company") announced today that it has secured its corporate headquarters by signing a 5-year lease for 10,400 square feet of space at Newtown Commons West, outside of Philadelphia. The site will serve as corporate headquarters, a clinical research site and a physical therapy training center of excellence."We are de ...


10.04.2017

Helius Medical Technologies Inc. Announces Upcoming Participation and Presentation at the Cowen and Company 37th Annual Healthcare Conference

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 02/22/17 -- Helius Medical Technologies, Inc. (TSX: HSM)(TSX: HSM.S)(OTCQB: HSDT) ("Helius" or the "Company") announced its upcoming presentation at the Cowen and Company 37th Annual Healthcare Conference, March 6-8, 2017, at the Boston Marriott Copley Place, Boston. President and CEO, Phillippe Deschamps will be presenting at 3:20pm EST on March 6, 2017.The presentation will be webcast, and a replay will be accessible for 90-days f ...


22.02.2017

Helius Medical Technologies Inc. Closes C$12.5 Million Public Offering of Class A Common Stock, Including Full Exercise of Over-Allotment Option

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 02/16/17 -- Helius Medical Technologies, Inc. (TSX: HSM)(TSX: HSM.S)(OTCQB: HSDT) ("Helius" or the "Company") announced the closing of its previously announced public offering (the "Offering") of 6,555,000 shares of Class A Common Stock (the "Shares"), including 855,000 Shares issued pursuant to the exercise, in full, of the over-allotment option granted to the Underwriters in connection with the Offering. The Sh ...


16.02.2017

Helius Medical Technologies Announces Publication of Multiple Sclerosis Pilot Study Results in Multiple Sclerosis Journal: Experimental, Translational and Clinical

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 02/09/17 -- Helius Medical Technologies, Inc. (TSX: HSM)(TSX: HSM.S)(OTCQB: HSDT) ("Helius") is pleased to announce that the clinical results from its Multiple Sclerosis (MS)-Pilot Study, performed at the Montreal Neurological Institute, were published in the peer reviewed journal Multiple Sclerosis Journal: Experimental, Translational and Clinical, January-March 2017:p1-9. The publication, "Non-invasive tongue stimulation combined with ...


09.02.2017

Helius Medical Technologies Announces Filing of Final MJDS Base Shelf Prospectus

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 01/26/17 -- Helius Medical Technologies, Inc. (TSX: HSM)(TSX: HSM.S)(TSX: HSM.WT.S)(OTCQB: HSDT) ("Helius" or the "Company") announced today that it has filed a final MJDS base shelf prospectus (the "Final Canadian Prospectus") with the securities commissions in each of the provinces of Canada. The Final Canadian Prospectus allows Helius, following the filing of a prospectus supplement, to issue various types of securities ...


26.01.2017

Helius Medical Technologies Announces Launch of Sixth Site for Pivotal Mild to Moderate Traumatic Brain Injury Clinical Trial

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 01/16/17 -- Helius Medical Technologies, Inc. (TSX: HSM)(OTCQB: HSDT) ("Helius" or the "Company") is pleased to announce that MedStar National Rehabilitation Hospital in Washington D.C., has been launched as the sixth site to provide services supporting Helius'' ongoing pivotal trial investigating PoNS™ Therapy for the treatment of subjects with balance disorder resulting from mild to moderate Traumatic Brain Injury (TBI). ...


16.01.2017

Helius Medical Technologies Announces Launch of Fifth Site for Pivotal Mild to Moderate Traumatic Brain Injury Clinical Trial

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 01/10/17 -- Helius Medical Technologies, Inc. (TSX: HSM) (OTCQB: HSDT) ("Helius" or the "Company") is pleased to announce that Virginia Commonwealth University (VCU) in Richmond, VA, has been launched as the fifth site to provide services supporting Helius'' ongoing pivotal trial investigating PoNS™ Therapy for the treatment of subjects with balance disorder resulting from mild to moderate Traumatic Brain Injury (TBI). Cli ...


10.01.2017

Helius Medical Technologies announces that its shelf registration filed on Form S-3 with the US Securities and Exchange Commission (SEC) has been made effective

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 01/09/17 -- Helius Medical Technologies, Inc. (TSX: HSM)(TSX: HSM.S)(OTCQB: HSDT) ("Helius") announced today that it has filed a shelf registration statement on Form S-3 with the United States Securities and Exchange Commission ("SEC"), which has now been made effective. The registration statement allows Helius to issue various types of securities, including common stock, debt securities and/or warrants, up to an aggregate amount of ...


09.01.2017

Full Enrollment Reached in Tactile Communication and Neurorehabilitation Laboratory Clinical Trial

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 12/05/16 -- Helius Medical Technologies, Inc. (TSX: HSM)(TSX: HSM.S)(OTCQB: HSDT) ("Helius") along with the Tactile Communication and Neurorehabilitation Laboratory (TCNL) of University of Wisconsin-Madison, are pleased to announce the last subject has been randomized in a 44-subject clinical trial, investigating PoNS™ Therapy for the treatment of chronic balance deficits due to traumatic brain injury (TBI), and the trial is now fully enrolled ...


05.12.2016

Helius Medical Technologies and HealthTech Connex Announce Preliminary Research Results

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 12/02/16 -- Helius Medical Technologies, Inc. (TSX: HSM)(TSX: HSM.S)(OTCQB: HSDT) ("Helius") and HealthTech Connex Inc, (HTC) are pleased to announce, based on favorable preliminary results, the expansion of a comprehensive study to further characterize physiological changes in improved cognitive function resulting from investigational PoNS™ Therapy in healthy subjects.Characterizing the brain''s healing response to neurological trau ...


02.12.2016

Helius Medical Technologies and U.S. Army Extend Sole Source Contract for the PoNS(TM) Device Testing and Development

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 11/21/16 -- Helius Medical Technologies, Inc. (TSX: HSM)(OTCQB: HSDT) ("Helius" or the "Company") announced that NeuroHabilitation Corporation ("NHC"), a division of Helius, successfully executed an amendment to the sole source cost sharing contract entered into with the U.S. Army Medical Research and Materiel Command (USAMRMC). The contract is extended to December 31, 2017 and allows Helius to include additional study sit ...


21.11.2016

Brain Injury Advocates Team Up to "Tackle TBI" in New Public Service Announcement

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 11/10/16 -- Helius Medical Technologies (TSX: HSM)(OTCQB: HSDT) ("Helius" or the "Company") in partnership with the Brain Injury Association of America, has launched "," a new Public Service Announcement (PSA) featuring patient and veteran advocate Montel Williams and former NFL player Marvin Washington. The PSA is designed to raise awareness of Traumatic Brain Injury (TBI) and concussions as growing health issues and to pr ...


10.11.2016

Helius Medical Technologies to Receive ISO 13485 Certificate

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 10/27/16 -- Helius Medical Technologies, Inc. (TSX: HSM)(OTCQB: HSDT) ("Helius" or the "Company") announced today that its wholly owned subsidiary, NeuroHabilitation Corporation, has been assessed by Lloyd''s Register Quality Assurance Limited (LRQA) and recommended for ISO 13485 certification for its Portable Neuromodulation Stimulator (PoNS™), an investigational non-invasive device designed to deliver neurostimulation th ...


27.10.2016

Helius Medical Technologies Announces Publication of Positive Results of Russian Pediatric Cerebral Palsy Pilot Study

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 09/06/16 -- Helius Medical Technologies, Inc. (TSX: HSM)(OTCQB: HSDT) ("Helius" or the "Company") announces that results from a pilot study, investigating the benefits of PoNS™ technology with physiotherapy in treating symptoms of pediatric Cerebral Palsy (CP), have been accepted for publication in the Russian "Journal of Restorative Medicine and Rehabilitation" (). Results of the study will be presented in an oral session ...


06.09.2016

Helius Opens New Site for Pivotal Mild to Moderate Traumatic Brain Injury Trial at HealthTech Connex in Surrey, British Columbia

NEWTOWN, PENNSYLVANIA and SURREY, BRITISH COLUMBIA -- (Marketwired) -- 08/31/16 -- Helius Medical Technologies, Inc. (TSX: HSM)(OTCQB: HSDT) ("Helius" or the "Company") is pleased to announce HealthTech Connex Inc. ("HTC") in Surrey, British Columbia, will be the fourth site for the company''s ongoing pivotal trial investigating PoNS™ Therapy for the treatment of subjects with balance disorder resulting from mild to moderate Traumatic Brain Injury (TBI). ...


31.08.2016

Helius Medical Technologies Appoints Thomas Griffin to Board of Directors and Chairman of the Audit Committee

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 08/08/16 -- Helius Medical Technologies, Inc. (TSX: HSM)(OTCQB: HSDT) ("Helius" or the "Company") a company focused on the treatment of neurological symptoms caused by disease or trauma, announced today that Thomas Griffin will join the Board of Directors, effective immediately. Mr. Griffin will also serve as Chairman of the Audit Committee.Tom is currently Vice President of Finance for Entellus Medical, Inc. (NASDAQ: ENTL), a medic ...


08.08.2016

Helius Medical Technologies Announces That Registration Statement on Form S-1 has Been Declared Effective

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 07/13/16 -- Helius Medical Technologies, Inc. (TSX: HSM)(OTCQB: HSDT) ("Helius" or the "Company") announced today that the Securities and Exchange Commission ("SEC") has declared effective the Company''s registration statement on Form S-1 relating to the resale of up to 11,953,115 shares of the Company''s Class A common stock, without par value (the "Common Shares), 5,074,560 warrants to purchase s ...


13.07.2016

MS Pilot Study Data to Be Presented at the International Neuropsychological Society Mid-Year Meeting in London (July 6-8)

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 07/05/16 -- Helius Medical Technologies, Inc. (TSX: HSM)(OTCQB: HSDT) ("Helius" or the "Company") is pleased to announce that the results from the Multiple Sclerosis (MS) Pilot Study, investigating PoNS™ Therapy, will be presented in London on July 6th, during the mid-year meeting for the International Neuropsychological Society (INS). The independent study took place at the Montreal Neurological Institute and Hospital and Concordia ...


05.07.2016

Helius Medical Announces Results from a Case Series of Subjects With Advanced MS

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 06/21/16 -- Helius Medical Technologies, Inc. (TSX: HSM)(TSX: HSM.S)(OTCQB: HSDT) ("Helius" or the "Company") is pleased to announce the results of a case series of individuals with advanced symptoms of Multiple Sclerosis (MS) treated with PoNS™ Therapy.This study was performed at TCNL(1), University of Wisconsin, Madison and the data was presented at the 2016, Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).Si ...


21.06.2016

Helius Medical Announces Proceeds of $1.4 Million From Exercise of Warrants

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 06/06/16 -- Helius Medical Technologies, Inc. (TSX: HSM)(OTCQB: HSDT) ("Helius" or the "Company") a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, is pleased to announce that it received proceeds of CDN $1,825,600 (approximately US$1,409,947) from the exercise of certain warrants issued in 2014, all of which was received after the Company''s fiscal year end on Marc ...


06.06.2016

Helius Medical Technologies Announces Resignation of Director

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 02/03/17 -- Helius Medical Technologies, Inc. (TSX: HSM)(TSX: HSM.S)(TSX: HSM.WT.S)(OTCQB: HSDT) ("Helius" or the "Company") announces the resignation of Savio Chiu from his position as a Director of the Company effective January 30, 2017 to pursue other opportunities. "I want to sincerely thank Mr. Chiu who has been a director for Helius Medical Technologies since its inception as a public company. His service to the company h ...


03.02.2017

Helius Medical Technologies Restates and Re-Files Historical Financial Statements for Non-Cash Reclassification of Warrants

NEWTOWN, PENNSYLVANIA -- (Marketwired) -- 04/26/16 -- Helius Medical Technologies, Inc. (TSX: HSM)(OTCQB: HSDT) ("Helius" or the "Company") - The Company is issuing the following press release to clarify its disclosure.Restated Financial StatementsThe Company has restated its interim financial statements for the periods ended June 30, 2015, September 30, 2015, and December 31, 2015 (collectively, the "Restated Financial Statements") in order to reflect the correct ...


26.04.2016



All members: 9 376
Register today: 1
Register yesterday: 1
Members online: 0
Guests online: 60


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.